In light of the program “Affordable Better” (in Dutch: Betaalbaar Beter”) by the Radboudumc and health insurances VGZ, a working group led by Nicole van de Kar (photo left), pediatric nephrologist and Jack Wetzels (photo below), nephrologist applied for funding to study the treatment scheme of the highly expensive orphan drug: Eculizumab.
This request for funding is supported by Zorgverzekeraars Nederland. With this funding, in total € 2.3 million, the treatment of atypical hemolytic uremic syndrome (aHUS) and Paroxysmal nocturnal hemoglobinuria (PNH) with Eculizumab can be further optimized.
This funding will be used to determine the qualitative optimal use of Eculizumab (in Dutch: Kwalitatief Optimaal Gebruik Eculizumab (KOGE)) by investigating if a shorter duration of treatment, together with lower dosage of eculizumab guided by serum levels, is safe and effective. The KOGE study will built upon the data gathered by the CUREiHUS study, a national multicenter study with participation of all academic hospitals.
<< back to overview news items